BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones

November 1, 2022

https://www.globenewswire.com/news-release/2022/11/01/2545315/29446/en/BioCryst-Reports-Third-Quarter-2022-Financial-Results-and-Upcoming-Key-Milestones.html

—$66.0 million in ORLADEYO Q3 2022 net revenue; on-track to more than double sales in 2022 vs 2021—

—Underlying patient trends remain strong with nine percent paid patient growth in Q3 2022—

Read more at globenewswire.com

Related news for (BCRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.